Such a safety profile, coupled with the preclinical efficacy of PRL3-zumab in orthotopic tumor models, lends support for further studies of PRL3-zumab in PRL3+ cancer patients as a safe, effective targeted therapy. This evidence concerns the gene PTP4A3 and neoplasm.